Compare Microchip Technology Inc. (MCHP) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Repligen Corporation Common Stock — how do they compare? Microchip Technology Inc. trades at $69.87 (market cap $38.69B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Microchip Technology Inc. is far larger — about 3.4× Repligen Corporation Common Stock's market cap, and Microchip Technology Inc. pays a 2.55% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 63 Days and Repligen Corporation Common Stock for 0 Days on average.
| MCHP | RGEN | |
|---|---|---|
Market Cap | $38.69B | $11.31B |
Volume | 14,380,005 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $102.97 | $194.57 |
52-Week Low | $49.02 | $102.87 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $43.82B | $11.20B |
Dividend Yield | 2.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $74.16, up 0.45% on the day, with a bearish technical signal but strong analyst consensus. The company has beaten EPS estimates for the last three quarters, though 2025 saw a net loss amid revenue contraction. Recent news highlights expansion in Ethernet and 48V power portfolios, along with the completed acquisition of Hailo, targeting growth in automotive, industrial, and AI infrastructure markets.
The outlook is mixed: robust buy-side analyst support and strategic positioning in high-growth sectors offer upside potential, but high valuation multiples, significant debt, and recent profitability challenges present risks. The consensus price target of $110.50 implies substantial appreciation, contingent on successful execution and market demand recovery.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
